# Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

> **NCT00355082** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 226 (actual)

## Conditions studied

- Epilepsy, Partial

## Interventions

- **DRUG:** lamotrigine, 300 mg/day
- **DRUG:** lamotrigine, 250 mg/day

## Key facts

- **NCT ID:** NCT00355082
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355082, "Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00355082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*